4-氯-7-异丙氧基-6-甲氧基-喹啉-3-甲腈 | 741276-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-7-异丙氧基-6-甲氧基-喹啉-3-甲腈
• 中文别名: 4-氯-7-异丙氧基-6-甲氧基喹啉-3-甲腈
• 英文名称: 7-isopropyloxy-6-methoxy-4-chloroquinoline-3-carbonitrile
• 英文别名: 4-Chloro-7-isopropoxy-6-methoxyquinoline-3-carbonitrile；4-chloro-6-methoxy-7-propan-2-yloxyquinoline-3-carbonitrile
• CAS: 741276-43-7
• 化学式: C₁₄H₁₃ClN₂O₂
• 分子量: 276.722
• InChiKey: GILOYPJGILGLIT-UHFFFAOYSA-N

物化性质

• 熔点：
  212℃
• 密度：
  1.28

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  55.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氯-7-异丙氧基-6-甲氧基-喹啉-3-甲腈 在 三氯化铝 作用下， 生成 4-氯-7-羟基-6-甲氧基喹啉-3-甲腈
  参考文献：
  名称：

  Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines

  摘要：

  Src is a nonreceptor tyrosine kinase involved in signaling pathways that control proliferation, migration, and angiogenesis. Increased Src expression and activity are associated with an increase in tumor malignancy and poor prognosis. Several quinolines and quinazolines were identified as potent and selective inhibitors of Src kinase activity. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00493-5
• 作为产物：
  描述：

  4-异丙氧基-3-甲氧基苯甲酸甲酯 在 硝酸 、 铁粉 、 氯化铵 、 三氯氧磷 作用下， 生成 4-氯-7-异丙氧基-6-甲氧基-喹啉-3-甲腈
  参考文献：
  名称：

  Inhibitors of Src tyrosine kinase: the preparation and structure–activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines

  摘要：

  Src is a nonreceptor tyrosine kinase involved in signaling pathways that control proliferation, migration, and angiogenesis. Increased Src expression and activity are associated with an increase in tumor malignancy and poor prognosis. Several quinolines and quinazolines were identified as potent and selective inhibitors of Src kinase activity. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00493-5

文献信息

• Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase
  作者：Xin Cao、Qi-Dong You、Zhi-Yu Li、Qing-Long Guo、Jing Shang、Ming Yan、Ji-Wang Chern、Men-Ling Chen

  DOI：10.1016/j.bmc.2008.04.065

  日期：2008.6

  Because both c-Src and iNOS are key regulatory enzymes in tumorigenesis, a new series of 4-heteroarylamino-3-quinolinecarbonitriles as potent dual inhibitors of both enzymes were designed, prepared, and evaluated for blocking multiple signaling pathways in cancer therapy. All compounds were evaluated by two related enzyme inhibition assays and an anti-proliferation assay in vitro. The results showed that most compounds could inhibit both enzymes, and several of them showed potent inhibition activity against different cancer cell lines. The best compound 20 (CPU-Y020) showed the IC(50) values of 6.58 and 7.61 mu M toward colon cancer HT-29 and liver cancer HepG2 cell lines. (C) 2008 Elsevier Ltd. All rights reserved.
• The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS
  作者：Xin Cao、Qi-Dong You、Zhi-Yu Li、Xiao-Rong Liu、Dan Xu、Qing-Long Guo、Jing Shang、Ji-Wang Chern、Meng-Ling Chen

  DOI：10.1016/j.bmcl.2008.10.006

  日期：2008.12

  Because both c-Src and iNOS are key regulatory enzymes in tumorigenesis, a new series of 4-heterocycle amine-3-quinolinecarbonitriles as potent dual inhibitors of both enzymes were designed, synthesized and evaluated as multiple targets agents in cancer therapy. All compounds were evaluated by two related enzyme inhibition assays and an anti-proliferation assay in vitro. The results showed that most compounds inhibited c-Src and iNOS well. The best compound 8 inhibited both enzymes with the IC(50) values of 34.8 nM and 26.7 mu M. Several compounds also showed moderate anti-proliferation at 10 mu M against colon and liver cancer cell lines. (C) 2008 Elsevier Ltd. All rights reserved.
• [EN] NEW ANTICANCER COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES ANTICANCEREUX, PROCEDE DE PREPARATION DE CES DERNIERS ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES
  申请人：REDDYS LAB LTD DR

  公开号：WO2004069145A2

  公开（公告）日：2004-08-19

  The present invention relates to novel anticancer agents, their pharmaceutically acceptable salts, their geometrical isomers and their pharmaceutically acceptable compositions containing them. the present invention more particularly relates to novel quinazoline compounds, their pharmaceutically acceptable salts and their pharmaceutically acceptable compositions containing them. the novel quinazoline compounds have the general formula (I), where all symbols are as defined in the specification.